| An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data International CLL-IPI Working Group The Lancet Oncology 17 (6), 779-790, 2016 | 643 | 2016 |
| Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia CD Herling, N Abedpour, J Weiss, A Schmitt, RD Jachimowicz, O Merkel, ... Nature communications 9 (1), 727, 2018 | 210 | 2018 |
| Sensitizing protective tumor microenvironments to antibody-mediated therapy CP Pallasch, I Leskov, CJ Braun, D Vorholt, A Drake, YM Soto-Feliciano, ... Cell 156 (3), 590-602, 2014 | 199 | 2014 |
| miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia CP Pallasch, M Patz, YJ Park, S Hagist, D Eggle, R Claus, ... Blood, The Journal of the American Society of Hematology 114 (15), 3255-3264, 2009 | 178 | 2009 |
| Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease CP Pallasch, A Schulz, N Kutsch, J Schwamb, S Hagist, H Kashkar, ... Blood, The Journal of the American Society of Hematology 112 (10), 4213-4219, 2008 | 77 | 2008 |
| CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial A Mackensen, JBAG Haanen, C Koenecke, W Alsdorf, E Wagner-Drouet, ... Nature Medicine 29 (11), 2844-2853, 2023 | 60 | 2023 |
| Long term follow‐up data and health‐related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG) N Kutsch, J Bahlo, S Robrecht, J Franklin, C Zhang, C Maurer, N De Silva, ... Hemasphere 4 (1), e336, 2020 | 50 | 2020 |
| Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany A Hamprecht, D Buchheidt, JJ Vehreschild, OA Cornely, B Spiess, G Plum, ... Eurosurveillance 17 (36), 20262, 2012 | 50 | 2012 |
| Results of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and … K Fischer, AM Fink, H Bishop, M Dixon, J Bahlo, MY Choi, R Weinkove, ... Blood 126 (23), 496, 2015 | 31 | 2015 |
| The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis. N Kutsch, J Bahlo, JC Byrd, H Dohner, B Eichhorst, M Else, C Geisler, ... Journal of Clinical Oncology 33 (15_suppl), 7002-7002, 2015 | 25 | 2015 |
| Hematologic rescue of CAR T-cell–mediated prolonged pancytopenia using autologous peripheral blood hematopoietic stem cells in a lymphoma patient P Gödel, N Sieg, JM Heger, N Kutsch, C Herling, BN Bärmann, C Scheid, ... Hemasphere 5 (3), e545, 2021 | 22 | 2021 |
| FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia N Kutsch, R Busch, J Bahlo, J Mayer, M Hensel, G Hopfinger, G Hess, ... Leukemia & lymphoma 58 (2), 399-407, 2017 | 19 | 2017 |
| Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial O Al‐Sawaf, B Gentile, J Devine, C Zhang, K Sail, M Tandon, AM Fink, ... American Journal of Hematology 96 (9), 1112-1119, 2021 | 17 | 2021 |
| Potential synergy between radiotherapy and CAR T-cells-a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy J Fan, A Adams, N Sieg, JM Heger, P Gödel, N Kutsch, D Kaul, M Teichert, ... Radiotherapy and Oncology 183, 109580, 2023 | 16 | 2023 |
| Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA JM Heger, J Mattlener, J Schneider, P Gödel, N Sieg, F Ullrich, R Lewis, ... Blood 143 (6), 522-534, 2024 | 13 | 2024 |
| First-line venetoclax combinations in fit patients with CLL: 4-year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial M Fürstenau, M Ritgen, S Robrecht, J Von Tresckow, C Zhang, ... Blood 142, 635, 2023 | 13 | 2023 |
| Evaluation of the international prognostic index for chronic lymphocytic leukemia (CLL-IPI) in elderly patients with comorbidities: analysis of the CLL11 Study Population V Goede, J Bahlo, N Kutsch, K Fischer, AM Fink, G Fingerle-Rowson, ... Blood 128 (22), 4401, 2016 | 11 | 2016 |
| THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS J Bahlo, N Kutsch, M Bergmann, J Byrd, H Doehner, B Eichhorst, M Else, ... Haematologica 100, 313-315, 2015 | 11 | 2015 |
| Efficacy and safety of the combination of tirabrutinib and entospletinib with or without obinutuzumab in relapsed chronic lymphocytic leukemia N Kutsch, C Pallasch, E Tausch, V Böhme, M Ritgen, R Liersch, A Wacker, ... Hemasphere 6 (4), e692, 2022 | 9 | 2022 |
| Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy M Fuerstenau, G Hopfinger, S Robrecht, AM Fink, O Al-Sawaf, ... Leukemia 34 (4), 1177-1181, 2020 | 9 | 2020 |
Michael HallekUniversity of Cologne在 uni-koeln.de 的电子邮件经过验证
